Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MHLW

Bayer symbol

EMA clears Bayer’s Stivarga for liver cancer

The multikinase inhibitor will treat patients with HCC

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

Bayer symbol

Bayer moves vilaprisan into phase III trials for uterine fibroids

ASTEROID study will investigate safety and efficacy of the novel drug

- PMLiVE

J+D expands its Asian reach

The UK-based group partners with Japanese consulting firm

Bayer symbol

Bayer wins FDA approval for MS electronic autoinjector and app

US regulator gives green light to Betaconnect and myBETA app

Bayer symbol

Bayer’s lymphoma drug copanlisib gets speedy FDA review

The PI3K inhibitor will be assessed for relapsed or refractory follicular lymphoma

Bayer symbol

FDA OK for Stivarga ends decade-long drought in liver cancer

Bayer's medicine wins US approval to treat hepatocellular carcinoma

- PMLiVE

Japanese pharma pulls no punches with post-Brexit UK

Firm want reassurance from the UK on its future in science and innovation

Choices, choices…

Not all innovative business models are equal

- PMLiVE

Xarelto beats aspirin for recurrent blood clots

Trial shows the NOAC reduces the risk of blood clots by 74%

- PMLiVE

Bayer: Post-truth politics severely handicaps innovation

And firm also voices its concerns over Brexit

- PMLiVE

Xarelto and Eylea continue to dominate Bayer’s pharma sales

And firm looks for turnaround in 2017 from Stivarga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links